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1. INTRODUCTION 
 
NOVEL DRUG DELIVERY SYSTEM 
 The basic rationale for controlled drug delivery is to alter the 
pharmacokinetics and pharmacodynamics of pharmacologically active moieties by 
using novel drug delivery system or by modifying the molecular structure and or 
physiological parameters inherent in a selected route of administration
1
. 
 The goal of drug delivery is to produce drug concentrations that elicit 
desired pharmacological actions and to minimize the incidents and severity of 
unwanted adverse effects. To achieve this goal it would be advantageous and more 
convenient to maintain a dosing frequency at once or at most a twice- daily regimen. 
 In conventional oral drug delivery system, there is little or no control 
over the release of the drug and effective concentration at the target side can be 
achieved by intermittent  administration of grossly excessive doses. This kind of 
dosing pattern results in constantly changing, unpredictable, and often 
subtherapeutic or supratherapeutic plasma concentrations, leading to marked side 
effective some case, moreover, the rate and extent of absorption of drug from 
conventional formulation may vary greatly depending on the factors such as 
physico-chemical properties of the drug, the presence of excipients, and various 
physiological factors. 
 Conventional dosages forms are rapidly absorbed with the ascending and 
descending portions of the concentrations versus time curves reflecting primarily the 
rate of absorption and elimination, respectively. Because of the rapid rate of 
absorption from conventional dosage forms, drugs are usually administered more 
than once daily with the frequency being dependent on biological half-life and 
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duration of pharmacological effect. The time of dosing may also be effected by 
therapeutic index of a drug. 
 Recently, several technical advancements have been made they have 
resulted in the development of new techniques for drug delivery . This techniques 
are capable of controlling the rate of drug delivery sustaining the duration of 
therapeutic activity and or targeting the delivery of drug to tissues
2
. 
Novel drug delivery system
3
 can be broadly classified into two groups. 
1. Sustained release drug delivery system (SRDDS). 
2. Controlled release drug delivery system(CRDDS) 
Sustained release drug delivery system: 
 SRDDS is described as pharmaceutical dosage form formulated to 
sustain the release of a therapeutic agent, such that its appearance in the systemic 
circulation is delayed and are prolonged and its plasma profile is sustained in 
duration. This leads to increase in duration of effects so that therapeutic effect is 
sustained.  
Controlled release drug delivery system: 
 The objective in designing a controlled drug delivery system is to provide for 
the release of a pharmacologically active agent in a predetermined predictable and 
reproducible manner. The rationale behind controlled release formulations is that a 
drug is more effective and exhibits less side effects when its concentration in the 
circulation is kept constant at some optimum level for prolonged periods of time. 
Fig.1.illustrates the expected drug concentration profiles for different methods of 
drug administrations. 
 The plasma concentration of the drug reaches a maximum (peak) with 
conventional dosage forms and then decrease (valley) at the point where repeated 
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administrations becomes necessary to maintain the plasma concentrations. Very 
often the initial concentration Is above the therapeutically effective level that may 
increase the risk of side effects. Conventional dosage forms can thus result in a drug 
regimen in which the drug concentration oscillates between altering periods of drug 
overdose and drug in efficiency. Controlled release formulations are expected to 
remove the peaks and valleys of drug concentration in the blood thus providing for a 
more effective regimen. It should be pointed out here that constant drug 
concentrations are not always necessary for the best treatment of disease. For 
example treatment of diabetes with fluctuating levels of insulin requires self-
modulated system, the rate of drug delivery can change continuously in response to 
the concentrations of a specific moiety in various triggered devices. Drug release 
does not takes place until it is activated by a specific a external moiety and more 
activated drug release takes place at a preprogrammed rate
4
. 
 
Figure 1: Drug level versus time profile showing differences between zero-
order controlled release, slow first-order sustained release, and 
immediate release
5
 
 The term “ Controlled release” implies predictability and reproducibility in 
drug release kinetics , which means that the release of drug ingredients from a 
controlled release drug delivery system proceeds at a rate profile i.e. not only 
predictable kinetically , but also reproducible from one unit to another. 
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 In recent years considerable attention has been focused on the 
development of controlled release drug delivery systems. Controlled release drug 
delivery systems are designed to release one or more drugs continuously in a 
predetermined pattern for a fixed period of time either systemically or to a specified 
target organ. Drug release from this system should be at a desired predictable and 
reproducible rate. The primary objectives of controlled release drug delivery are to 
ensure safety and to improve efficacy of drugs as well as patient compliance. 
Controlled release drug delivery systems have been designed for oral parental, 
implantable and transdermal route. 
 The benefits of intravenous infusion closely duplicated, without its 
hazards by using the skin as the port of drug administration to provide continuous 
transdermal drug infusion into the systemic circulation. 
 Transdermal drug delivery systems (TDDS)
6 
are defined as self 
contained, discrete dosage forms which, when applied to intact skin, deliver the 
drug(s), through the skin, at a controlled rate to systemic circulation. The 
transdermal route of administration is recognized as one of the potential route for the 
local and systemic delivery of drugs. In comparison to conventional pharmaceutical 
dosage forms, TDDS offer many advantages, such as elimination of first pass 
metabolism, sustained drug delivery, reduced frequency of administration, reduced 
side effects and improved patient compliance.  
 To provide continuous drug infusion through the intact skin, membrane 
moderated systems, adhesive diffusion controlled systems, matrix dispersion type 
systems and micro reservoir systems have been developed for the topical application 
on to the intact skin surface to control the delivery of drug and its subsequent 
permeation through the skin tissue. In membrane moderated systems, drug reservoir 
is encapsulated in a shallow compartment moulded from a drug impermeable 
metallic plastic laminate and a rate controlling polymeric membrane which may be 
micro porous or non-porous. The drug molecules are permitted to release only 
through the rate controlling polymeric membrane. Membrane moderated systems 
were developed in this investigation, as they are easy to fabricate in a wide range of 
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sizes and the constant release rate of the drug is the major advantage of membrane 
permeation controlled system. 
 Continuous intravenous infusion is recognized as a superior mode of 
drug delivery not only to bypass hepatic „‟first-pass” elimination, but also to 
maintain a constant, prolonged and therapeutically effective drug level in the body. 
A closely monitored intravenous infusion can provide the advantage of drug into the 
systemic circulation and control of circulating drug levels. However this mode of 
drug delivery involves certain risks. 
 Recently there has been a growing recognition that the benefits of 
intravenous infusion can be closely duplicated without its hazards, by using the 
intact skin as the port of drug administration to provide continuous drug delivery 
into the systemic circulation
7
. This is known as the transdermal administration and 
the drug delivery systems are known as “transdermal therapeutic systems” or 
popularly as “transdermal patches”. 
 Transdermal drug delivery systems
8
 are adhesive drug containing devices 
of defined surface area that deliver a predetermined amount of drug to the surface of 
intact skin at a programmed rate. These systems provide drug systemically at a 
predictable rate and maintain the rate for extended period of time thus eliminating 
numerous problems associated with oral dosing including product stability, 
bioavailability and the peaks and troughs of pulse dosing. 
ADVANTAGES & DISADVANTAGES TRANSDERMAL DRUG DELIVERY 
SYSTEMS
9, 10, 11, 12: 
Advantages: 
1. Transdermal medication delivers a steady infusion of a drug over an 
extended period of time. Adverse effects or therapeutic failures 
frequently associated with intermittent dosing can also be avoided. 
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2. Transdermal delivery can increase the therapeutic value of many 
drugs by avoiding specific problems associated with the drug e.g., 
gastro-intestinal irritation, low absorption, decomposition due to 
hepatic „‟first- pass” effect, formation of metabolites that cause side 
effects, short half-life necessitating frequent dosing etc. 
3. Due to the above advantage, it is possible that an equivalent 
therapeutic effect can be elicited via transdermal drug input with a 
lower daily dose of the drug than is necessary, if, for example, the 
drug is given orally. 
4. The simplified medication regimen leads to improved patient 
compliance and reduced inter & intra – patient variability. 
5. At times the maintenance of the drug concentration within the bio 
phase is not desired. Application and removal of transdermal patch 
produce the optimal sequence of pharmacological effect. 
6. Self administration is possible with these systems. 
7. The drug input can be terminated at any point of time by removing 
transdermal patch. 
Disadvantages: 
1. The drug must have some desirable physicochemical properties for 
penetration through stratum corneum and if the drug dose required 
for therapeutic value is more than 10 mg/day, the transdermal 
delivery will be very difficult. 
2. Only relatively potent drugs are suitable candidates for TDDS 
because of the natural limits of drug entry imposed by the skin‟s 
impermeability. 
3. Some patients develop contact dermatitis at the site of application 
for one or more of the system components, necessitating 
discontinuation. 
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4. Clinical need is another area that has to be examined carefully 
before a decision is made to develop a transdermal product. 
5. The barrier function of the skin changes from one site to another on 
the same person, from person to person and with age. 
DRUG PERMEATION THROUGH SKIN: 
Skin as a Site for drug infusion: 
 The skin of an average adult body covers a surface area of approximately 
2 square meters and receives about one-third of the blood circulating through the 
body
13
.The skin is a multilayered organ composed of many histological layers.  
Structure and physiology of skin: 
Macroscopically skin comprises of three layers 
1. The epidermis,  
2. The dermis, 
3. The hypodermis. 
Epidermis: 
 The epidermis is a stratified, squamous, keratinizing epithelium. The 
keratinocytes comprise the major cellular component and are responsible for the 
evolution of barrier function. 
 Microscopically, the epidermis can be divided into five distinct strata 
with stratum corneum forming the outer most layer of the epidermis, exposing to the 
external environment which correspond to the consecutive steps of keratinocyte 
differentiation.  
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Five strata of epidermis as shown in Figure 2. 
 The ultimate result of this differentiation process is formation of the 
functional barrier layer, the stratum corneum. 
The five stratum include 
1. Stratum basale 
2. Stratum spinosum 
3. Stratum granulosum 
4. Stratum lucidum 
5. Stratum corneum 
Stratum basale: 
 The stratum basale or basal layer is responsibility for the continual 
renewal of the epidermis proliferation of the stem cells in stratum basale and creates 
new keratinocytes pushing the existing towards the surface thus they begin to 
differentiate finally achieving terminal differentiation in the stratum corneum. 
Stratum spinosum: 
 The next layer of epidermis is the stratum spinosum named for the 
numerous spiny projections (desmosomes on the cell surface). The keratinocytes 
maintain a complete set of organelles and also include membrane coating granules 
(or lamellae bodies) which originate in the golgi. 
Stratum Granulosum 
 The stratum granulosum is also called as granular layer characterized by 
numerous keratokyalin granules present in the cytoplasm of the more flattened, yet 
still viable, keratinocyte more lamellar bodies are also apparent and concentrate on 
the upper part of granulae cells. These contain stacks of flattened lipid vesicles. 
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Stratum Lucidum 
 The transition layer, the stratum lucidum comprises flattened cells which 
are not easy to visualize microscopically, the cellular organelles are broken down 
leaving only keratin filaments in the stratum granulosum, a inter filament matrix 
material in the intracellular compartment. The membrane coating granules fuse with 
the cell membrane and release their contents into the intercellular space. 
 These inter cellular lipids organize into multilamellar domains. Finally in 
the stratum corneum the outer most layer, protein is added to the inner surface of the 
cell membrane to form a cornified envelope that further strengthens the resistance of 
the cell. 
Stratum corneum 
 It forms the primary barrier to dermatological delivery and consists of 
horny, flat, polyhedral shaped, non –nucleated cells approximately 40 µm in 
diameter and  0.5 µm thick called as corneocytes. These corneocytes are cell 
remnants of the terminally differentiated keratinocytes present in the upper layer of 
the viable epidermis. 
 These are surrounded by a layer of cross-linked proteins and covalently 
linked lipid. The intercellular lipids of the stratum cornuem include number of 
phospholipids comprising approximately equimolar mixture of ceramides, 
cholesterol and free fatty acids. These non-polar and somewhat rigid components of 
the stratum corneum play a critical role in barrier function to chemical penetration 
and permeation. 
The diffusion pathways across the stratum corneum are 
1. Inter cellular lipid 
2. Pores 
3. Hair follicles 
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Dermis: 
 The dermis is composed of network of collagen and elastin fibres 
embedded in a mucopolysaccharide matrix, that also contain blood vessels, 
lymphatics, and nerve endings and which provides physiological support for the 
epidermis. 
Hypodermis: 
 Essential to the healthy function of the dermis and epidermis. 
 The hypodermis is mainly composed of fat cells that cushion the upper 
layer absorb nutrients, oxygen and moisture from the blood and remove toxic waste. 
 This subcutaneous layer contains glands and other skin structures, as well 
as sensory receptors involved in the sense of touch. 
 
Figure 2: Structure of epidermis 
  
61 
 The various skin tissue layers can be represented by a simplistic 
multilayer model as shown in Figure 3. 
 
Figure 3: A cross-section of human skin 
Skin as a membrane: 
 An average human skin surface is known to contain, on the average, 40-
70 hair follicles and 200-250 sweat ducts on each square centimeter of skin area. 
These skin appendages, however, actually occupy, grossly, only 0.1% of the total 
human skin surface. Even though the foreign agents, especially the water-soluble 
ones, may be able to penetrate into the skin via these skin appendages at a rate which 
is faster than through the intact area of the stratum corneum, this trans-appendageal 
route of percutaneous absorption has, at steady state, a very limited contribution to 
the over all kinetic profile of transdermal permeation. Therefore, the transdermal 
permeation of most neutral molecules can, thus, be considered as, a process of 
passive diffusion through the intact stratum corneum in the interfollicular region. So, 
for the sake of mechanistic analysis of transdermal drug infusion
14
 from stratum 
corneum the following model (figure 3) can be used. In the case that the skin serves 
as the point of administration for systemically active drugs, the drug applied 
topically will be absorbed, first into the systemic circulation and then transported to 
target tissues. 
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Mechanisms of Transdermal Permeation: 
 For a systemically active drug to reach a target tissue, it has to posses 
some physico-chemical properties which facilitate the sorption of the drug through 
the skin (Figure: 3), and also the uptake of the drug by the capillary network in the 
dermal papillary layer (Figure:5). Various events governing percutaneous absorption 
are shown in (Figure:4). 
 
       
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Events governing percutaneous absorption 
Diffusion of drug through vehicle  
to skin surface 
Transepidermal route Transfollicular route 
Partitioning in to stratum 
           corneum 
Partitioning in to sebum 
Diffusion through protein-lipid 
matrix of stratum corneum 
Diffusion through lipids in 
sebaceous pore 
Partitioning in to viable epidermis 
Diffusion through cellular mass of upper epidermis 
Diffusion through fibrous mass of upper dermis 
Capillary up taken and systemic dilution 
Dissolution of drug in vehicle 
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 The rate of permeation, dQ/dt, across various layers of skin tissues can be 
expressed as. 
 
(1) ----- )( rds CCP
dt
dQ

 
Where, Cd and Cr are respectively, the concentrations of skin penetrant in the donor 
phase (stratum corneum) and the receptor phase (systemic circulation); and Ps is the 
overall permeability coefficient of the skin and is defined by  
 
(2) -----  
s
sss
s
h
DK
P 
 
Where, Ks = Partition coefficient of the penetrant 
 Dss = Apparent diffusivity of penetrant 
 hs = Thickness of skin 
 Thus, permeability coefficient (PS) may be a constant since Ks; Dss and hs 
terms in equation (2) are constant under the given set of conditions.  
 A constant rate of drug permeation achieved, if Cd>Cr, then the equation 
(1) may be reduced to 
 
(3) ----- . ds CP
dt
dQ

 
 And the rate of skin permeation (dQ/dt) becomes a constant, if the Cd 
value remains fairly constant throughout the course of skin permeation. To maintain 
the Cd at a constant value, it is critical to make the drug to be released at a rate (Rr) 
which is always greater than the rate of skin uptake (Ra), i. e., Rr>>Ra . 
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Figure 5: Diagrammatic illustration of the relationship between the rate of 
drug release (Rr) and the rate of drug uptake (Ra) by the skin 
 By doing so, the drug concentration on the skin surface (Cd) is 
maintained at a level which is always greater than the equilibrium (or saturation) 
solubility of the drug in the stratum corneum (C
e
s), i.e., Cd>>C
e
s;  and a maximum 
rate of skin permeation (dQ/dt)m ,as expressed by equation (4),is thus reached: 
 
e
ss
m
CP
dt
dQ






 
 Apparently, the magnitude of (dQ/dt) m is determined by the skin 
permeability coefficient (PS) of the drug and its equilibrium solubility in the stratum 
corneum (C
e
s). 
BASIC COMPONENTS OF TRANSDERMAL DRUG DELIVERY SYSTEM
15  
The components of transdermal patch includes: 
1. Polymer matrix or matrices 
2. The drug  
3. Permeation enhancers and  
4. Other excipients. 
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Polymer matrix or matrices: 
 It is the rate controlling polymeric membrane which regulates the release 
rate of drug during a predetermined time interval. The following criteria should be 
satisfied for a polymer to be used in the transdermal system
16
.  
1. Molecular weight, glass transition temperature and chemical 
functionality of the polymer should be such that the specific drug 
diffuses properly and gets released through it. 
2. The polymer should be stable, non reactive with drug, easily 
manufactured and fabricated into the desired product and 
inexpensive. 
3. The polymer and its degradation products must be non toxic or non 
antagonistic to the host. 
4. The mechanical properties of the polymer should not deteriorate 
excessively when large amount of active agents are incorporated 
into it. 
The Drug: 
 For successfully developing a transdermal drug delivery system, the drug 
should be chosen with great care. The following are some of the desirable properties 
of a drug for transdermal delivery
17
. 
A.  Physicochemical Properties: 
1. The drug should have molecular weight less than approximately 
1000 Daltons. 
2. The drug should have affinity for both lipophillic and hydrophilic 
phases. Extreme partitioning characteristics are not conducive to 
successful delivery via the skin. 
3. The drug should have a low melting point. 
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B.  Biological Properties: 
1. The drug should be potent with a daily dose of the order of a few 
mg/day. 
2. The half-life (t1/2) of the drug should be short. 
3. The drug must not induce a cutaneous irritant / allergic response. 
4. Drugs which degrade in the GIT or which are inactivated by hepatic 
first pass effect are suitable candidates for transdermal delivery. 
5. Tolerance to the drug must not develop under the near zero order 
release profile of transdermal delivery. 
6. Drugs which have to be administered for a long period time or 
which cause adverse effects to non target tissue can also be 
formulated for transdermal delivery. 
Permeation Enhancers: 
 Three pathways are suggested for drug penetration through the skin: 
polar, non-polar, and polar/non-polar. The enhancers act by altering one of these 
pathways. The key to altering the polar pathway is to cause protein conformational 
change or solvent swelling. The key to altering the nonpolar pathway is to alter the 
rigidity of the lipid structure and fluidize the crystalline pathway (this substantially 
increases diffusion). The fatty acid enhancers increase the fluidity of the lipid 
portion of the stratum corneum
18, 19
. Some enhancers (binary vehicles) act on both 
polar and nonpolar pathways by altering the multi laminate pathway for penetrants. 
Enhancers can increase the drug diffusivity in the stratum corneum by dissolving the 
skin lipids or by denaturing skin proteins. The type of enhancer employed has a 
significant impact on the design and development of the product. 
 The success of dermatological drug products that are intended for 
systemic drug delivery, such as the transdermal, depends on the ability of the drug to 
penetrate through the skin in sufficient quantities to achieve its desired therapeutic 
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effect. The methods employed for modifying the barrier properties of the stratum 
corneum  to enhance the drug penetration (and absorption) through the skin can be 
categorized as (1) Chemical and (2) physical methods of enhancement
20 
A.  Chemical Enhancers:  
 Chemicals that promote the penetration of topically applied drugs are 
commonly referred to as accelerants, absorption promoters, or penetration 
enhancers. Chemical enhancers act by  
1. Increasing the drug permeability through the skin by causing 
reversible damage to the stratum corneum. 
2. Increasing (and optimizing) thermodynamic activity of the drug 
when functioning as co solvent. 
3. Increasing the partition coefficient of the drug to promote its release 
from the vehicle into the skin. 
4. Conditioning the stratum corneum to promote drug diffusion. 
5. Promoting penetration and establish drug reservoir in the stratum 
corneum. 
B.  Physical enhancers:  
 The iontophoresis and ultra sound (also known as phonophoresis or 
sonophoresis) techniques are examples of physical means of enhancement that have 
been used for enhancing percutaneous penetration (and absorption) of various 
therapeutic agents. 
Other Excipients: 
A.  Adhesives: 
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 The fastening of all transdermal devices to the skin has been done by 
using a pressure sensitive adhesive. The pressure sensitive adhesive can be 
positioned on the face of the device or in the back of the device and extending 
peripherally. The adhesive used in transdermal drug delivery system should fulfill 
the following criteria
21
. 
1. Should not irritate or sensitize the skin or cause an imbalance in the 
normal skin flora during its contact time with the skin. 
2. Should adhere to the skin aggressively during the dosing interval 
without its position being disturbed by activities such as bathing, 
exercise etc. 
3. Should be easily removed  
4. Should not leave an unwashable residue on the skin. 
5. Should have excellent contact with the skin at macroscopic and 
microscopic level. 
The face of adhesive system should also fulfill the following criteria. 
a) Physical and chemical compatibility with the drug, excipients and 
enhancers of the device of which it is a part. 
b) Permeation of the drug should not be affected. 
B.  Backing membrane: 
 Backing membranes are flexible and they provide a good bond to the 
drug reservoir, prevent drug from leaving the dosage form through the top, and 
accept printing. It is impermeable substance that protects the product during use on 
the skin e.g. metallic plastic laminate, plastic backing with absorbent pad and 
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occlusive base plate (aluminum foil),adhesive foam pad (flexible poly urethane) 
with occlusive base plate (aluminum foil disc) etc. 
APPROACHES TO DEVELOPMENT OF TRANSDERMAL THERAPEUTIC SYSTEMS22: 
 Several technologies have been successfully developed to provide a rate 
control over the release and the transdermal permeation of drugs. These technologies 
can be classified into four approaches as follows: 
1. Membrane permeation – controlled systems 
2. Adhesive dispersion – type systems. 
3. Matrix diffusion – controlled systems. 
4. Micro reservoir type or micro sealed dissolution controlled 
systems. 
1. Membrane Permeation – Controlled Systems:  
 In this type of system drug reservoir is encapsulated in a shallow 
compartment moulded from a drug impermeable metallic plastic laminate and a rate 
controlling polymeric membrane which may be micro porous or non-porous. The 
drug molecules are permitted to release only through the rate controlling polymeric 
membrane. In the drug reservoir compartment, the drug solids are either dispersed 
homogenously in a solid polymer matrix (e.g. Polyisobutylene adhesive) or 
suspended in an unbleachable, viscous liquid medium (e.g. Silicon fluids) to form a 
paste like suspension.  
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Figure 6: The cross-sectional view of a membrane moderated transdermal 
drug delivery system, showing various major structural components 
 The rate of drug release from this type of system can be tailored by 
varying the polymer composition, permeability coefficient and thickness of the rate 
limiting membrane and adhesive. The constant release rate of the drug is the major 
advantage of membrane permeation controlled system. Examples of this system are  
a) Transderm – Nitro: Nitroglycerin releasing transdermal system for 
once a day medication in angina pectoris. 
b) Transderm – Scop:  Scopolamine releasing transdermal system for 
72 hrs. Prophylaxis of motion sickness. 
c) Catapres: Clonidine releasing transdermal system for 7 day therapy 
of hypertension. 
d) Estraderm: Estradiol releasing transdermal system for treatment of 
menopausal syndrome for 3 – 4 days.  
 The membrane permeation controlled technology has also been used for 
controlled percutaneous absorption of prostaglandin derivatives. 
2. Adhesive Dispersion – Type Systems: 
 This is a simplified form of the membrane permeation controlled system. 
As represented in Figure:6, the drug reservoir is formulated by directly dispersing 
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the drug in an adhesive polymer e.g. Poly (isobutylene) or poly (acrylate) adhesive 
and then spreading the medicated adhesive, by solvent casting or hot melt, on to a 
flat sheet of drug impermeable metallic plastic backing to form a thin drug reservoir 
layer. 
 On the top of the drug reservoir layer, thin layers of non medicated, rate 
controlling adhesive polymer of a specific permeability and constant thickness are 
applied to produce an adhesive diffusion – controlled delivery system. Examples are  
 Frandol tape: Releases Isosorbide dinitrate for once-a-day medication of 
angina pectoris. 
 Deponit: Delivers nitroglycerine for the treatment of angina pectoris. 
 
Figure 7: Adhesive diffusion-controlled transdermal drug delivery system 
3. Matrix Diffusion- Controlled Systems: 
 In this approach, the drug reservoir is formed by homogenously 
dispersing the drug solids in a hydrophilic or lipophillic polymer matrix. The 
resultant medicated polymer is then moulded into a medicated disc with a defined 
surface area and controlled thickness. The dispersion of drug particles in the 
polymer matrix can be accomplished by either homogeneously mixing the finely 
ground drug particles with a liquid polymer or a highly viscous base polymer 
followed by cross-linking of the polymer chains or homogeneously blending drug 
solids with a rubbery polymer at an elevated temperature. The drug reservoir can 
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also be formed by dissolving the drug and the polymer in a common solvent 
followed by solvent evaporation in a mould at an elevated temperature and/or 
vacuum. This drug reservoir containing polymer disc is then pasted onto an 
occlusive base plate in a compartment fabricated from a drug impermeable plastic 
backing membrane. Instead of applying the adhesive polymer directly on the surface 
of the medicated disc as discussed earlier in the first two types of transdermal 
delivery systems, the polymer is spread along the circumference of the patch to form 
an adhesive rim around the medicated disc.  
 E.g., Nitro-Dur: Delivers nitroglycerin for the treatment of angina 
pectoris. 
 
Figure 8: The cross-sectional view of a matrix dispersion-type transdermal 
drug delivery system, showing various major structural components. 
4. Micro Reservoir Type or Micro Sealed Dissolution Controlled 
Systems  
  The micro reservoir type drug delivery system can be considered a 
combination of the reservoir and matrix diffusion type drug delivery systems. In this 
approach, the drug reservoir is formed by first suspending the drug solids in the 
aqueous solution of water soluble liquid polymer (e.g. Polyethylene glycol) and then 
dispersing the drug suspension homogenously in lipophillic polymer viz. silicone 
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elastomers by high energy dispersion technique to form several discrete, unleachable 
micro spheres of drug reservoirs. This thermodynamically unstable dispersion is 
quickly stabilized by immediately cross-linking the polymer chains in-situ, which 
produces a medicated polymer disc with a constant surface area and a fixed 
thickness. A transdermal therapeutic system is then produced by positioning the 
medicated disc at the centre and surrounding it with an adhesive rim. 
 E.g., Nitroglycerin: Releasing transdermal therapeutic system for once a 
day treatment of angina pectoris 
 
Figure 9: The cross-sectional view of a micro reservoir-type transdermal drug 
delivery system, showing various major structural components 
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2. DRUG AND EXCIPIENT PROFILE 
 
VERAPAMIL HYDROCHLORIDE
23 
Name of the drug : Verapamil hydrochloride 
Chemical name         : 5-(3, 4-Dimethoxyphenethyl)methylamino-2-(3,4-
dimethoxy Phenyl)-2-isopropylvaleronitrile mono 
hydrochloride. 
Formula              : C27H38N2O4 HCl  
Molecular weight : 491.06  
Structure  :   
 
P
Ka                                            
:  8.6 
Dose                          :     The drug should be administered with food. 
a)  240 mg each morning,  
b)  180 mg each morning plus 180 mg each evening, or 240 mg                                                       
each morning plus 120 mg each evening  
c)  240 mg every twelve hours.  
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Dosage form            : Tablets, capsules 
Description   : White crystalline powder, practically odorless and has a 
bitter taste. 
Solubility             : Soluble in water, freely soluble in chloroform, sparingly 
                                       Soluble in alcohol, Practically insoluble in ether. 
Category             : Antihypertensive 
Brands Available    : Isoptin, Calaptin, Veramil. 
Pharmacology : 
Mechanism of action : 
 Verapamil exerts antihypertensive effects by decreasing systemic 
vascular resistance, usually without orthostatic decreases in blood pressure or reflex 
tachycardia; bradycardia (rate less than 50 beats/min) is uncommon (1.4%).  
 It is a calcium ion influx inhibitor that experts its pharmacological effects 
by modulating the influx of ionic calcium across the cell membrane of the arterial 
smooth muscle as well as in conductile and contractile myocardial cells. 
Pharmacokinetics: 
Absorption: 
 About 90 % of Verapamil is absorbed from the gastro-intestinal tract.  
Absorption is rapid and the peak plasma concentration is reached 30-120 minutes 
following an oral dose. Verapamil undergoes extensive first-pass metabolism by the 
Liver.  Bioavailability ranges from 20 to 35%. 
Volume of distribution: 
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 The volume of distribution is 2.4-6.2 lit/Kg.  
Elimination half life: 
 The mean elimination half-life following single oral doses is 4-6 hours.   
Metabolism: 
 Verapamil undergoes an extensive hepatic metabolism. Due to a large 
hepatic first-pass effect, bio-availability does not exceed 20 - 35% in normal 
subjects. 
Elimination: 
 Kidney: About 70% of the administered dose is excreted in urine 
within 5 days as metabolites, of which 3-4% is excreted as 
unchanged drug. 
 Feces: About 16% of the ingested dose is excreted within 5 days in 
feces as metabolites.         
 Breast milk: Verapamil may appear in breast milk. 
Contraindication: 
 Verapamil HCl is contraindicated in: 
1. Severe left ventricular dysfunction  
2. Hypotension (systolic pressure less than 90 mmHg) or cardiogenic 
shock 
3. Sick sinus syndrome (except in patients with a functioning artificial 
ventricular pacemaker) 
4. Second- or third-degree Atrio-Ventricular block (except in patients 
with a functioning artificial ventricular pacemaker). 
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5. Patients with atrial flutter or atrial fibrillation and an accessory 
bypass tract (e.g., Wolff- Parkinson-White, syndromes). 
6. Patients with known hypersensitivity to verapamil hydrochloride. 
Drug Interactions:  
 Aspirin: In a few reported cases, co-administration of verapamil with 
aspirin has led to increased bleeding time greater than observed with aspirin alone. 
 Grapefruit juice: The intake of grapefruit juice may increase drug levels 
of verapamil. 
 Digitalis: Chronic verapamil treatment can increase serum digoxin levels 
by 50 to 75% during the first week of therapy, and this can result in digitalis 
toxicity. Maintenance and digitalization doses should be reduced when verapamil is 
administered, and the patient should be carefully monitored to avoid over or under 
digitalization. 
 Antihypertensive Agents: Verapamil administered concomitantly with 
oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme 
inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering 
blood pressure. 
Adverse reactions: 
 Cardiovascular: angina pectoris, atrio-ventricular dissociation, chest 
pain, myocardial infarction. 
 Digestive System: diarrhea, dry mouth, gastrointestinal distress. 
 Nervous System: cerebro vascular accident, confusion, insomnia, muscle 
cramps, psychotic symptoms,  
 Skin: Arthralgia and rash, hair loss hyperkeratosis, sweating, urticaria. 
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 Special Senses: blurred vision, tinnitus. 
 Storage:  Preserve in tight, light-resistant containers. Store at 25°C 
excursions permitted between 15–30°C.        
POLYMER PROFILES 
ETHYL CELLULOSE
24 
Chemical name : Cellulose Ethyl ether  
Molecular formula : C12 H23 O6 (C12 H22 O5) n C12 H22 O5 
Melting point : 129-133
°
c. 
Description : A taste less, free flowing white to light tan colored powder 
Category  : Coating agent, tablet binder, viscosity-increasing agent, and 
tablet filler. 
Solubility  : Ethyl cellulose is practically insoluble in glycerin, 
propylene glycol, and water. Ethyl cellulose that contains 
not less than 46.5% of ethoxyl groups is freely soluble in 
chloroform, ethanol (95%), ethyl acetate, methanol, and 
toluene. 
Applications in pharmaceutical formulations:  
 The main use of ethyl cellulose in oral formulation is as a hydrophobic 
coating agent for tablets and granules. Ethyl cellulose coatings are used to modify 
the release of a drug, to make an unpleasant taste, (or) to improve the stability of a 
formulation.  
Uses: 3-20% for sustained release tablets. 
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 10-20% for micro encapsulation. 
           1- 3% for tablet loading. 
           1-3% for tablet granulation. 
 Safety: Ethyl cellulose is widely used in oral and topical pharmaceutical 
formulations. It is also used in food products. Ethyl cellulose is generally regarded 
as nontoxic, nonirritant and non-allergenic material. As ethyl cellulose is not 
considered to be a health hazard, the WHO has not specified an acceptable daily 
intake. 
 Storage Seal it and stored in dry place. 
CELLULOSE ACETATE
25 
Nonproprietary Names 
 BP: Cellulose acetate 
 PhEur: Cellulosi acetas 
 USPNF: Cellulose acetate 
Synonyms 
 Acetyl cellulose; cellulose diacetate; cellulose triacetate. 
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Structural Formula 
 
Functional Category 
 Coating agent;  extended release agent; tablet and capsule diluent. 
Applications in Pharmaceutical Formulation or Technology 
 Cellulose acetate is widely used in pharmaceutical formulations both in 
sustained-release applications and for taste masking. 
  Cellulose acetate is used as a semi permeable coating on tablets, 
especially on osmotic pump-type tablets and implants. This allows for controlled, 
extended release of actives. Cellulose acetate films, in conjunction with other 
materials, also offer sustained release without the necessity of drilling a hole in the 
coating as is typical with osmotic pump systems. Cellulose acetate and other 
cellulose esters have also been used to form drug loaded micro particles with 
controlled release characteristics. Cellulose acetate films are used in transdermal 
drug delivery systems and also as film coatings on tablets or granules for taste 
masking. For example, acetaminophen granules have been coated with a cellulose 
acetate based coating before being processed to provide chewable tablets. Extended 
release tablets can also be formulated with cellulose acetate as a directly 
compressible matrix former. The release profile can be modified by changing the 
ratio of active to cellulose acetate and by incorporation of plasticizer, but was shown 
to be insensitive to cellulose acetate molecular weight and particle size distribution. 
Therapeutically, cellulose acetate has been used to treat cerebral aneurysms, and also 
for spinal perimedullary arteriovenous fistulas.  
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Description 
 Cellulose acetate occurs as a white to off-white powder, free-flowing 
pellets, or flakes. It is tasteless and odorless, or may have a slight odor of acetic acid. 
Glass transition temperature : 170–190°C 
Melting point :  melting range 230–300°C 
Solubility  : In general, cellulose acetates are soluble in 
acetone–water blends of varying ratios, 
dichloromethane–ethanol blends, dimethyl 
formamide, and dioxane. The cellulose acetates 
of higher acetyl level are generally more limited 
in solvent choice than are the lower acetyl 
materials. 
Stability and Storage Conditions 
 Cellulose acetate is stable if stored in a well closed container in a cool, 
dry place. Cellulose acetate hydrolyzes slowly under prolonged adverse conditions 
such as high temperature and humidity, with a resultant increase in free acid content 
and odor of acetic acid. 
Safety 
 Cellulose acetate is widely used in oral pharmaceutical products and is 
generally regarded as a nontoxic and nonirritant material. 
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3. LITERATURE REVIEW 
 
 Jatin Sood26 et al (2013) studied on matrix-type transdermal patches of 
verapamil hydrochloride (VPL) with combinations of hydroxyl propyl methyl 
cellulose (HPMC) and hydroxyl propyl cellulose (HPC) as matrix polymers and to 
investigate the influence of oleic acid (OA) on in vitro permeation of VPL through 
rat skin. The permeation studies were performed using Franz-type diffusion cells 
and full-thickness excised abdominal rat skin. The effect of the polymers on the drug 
release, percentage moisture loss, percentage moisture absorption, folding 
endurance, and thickness, were investigated. In vitro release studies showed zero-
order release of the drug from all the patches, and the mechanism of release was 
diffusion mediated. Data was analysed using different release kinetic models. In 
vitro release profiles showed that from optimized combination the release of the 
drug was sustained and it extended over a period of 24 hr VPM 006 emerged as the 
most satisfactory formulation as far as its technological properties were concerned. 
 Gungor S27 et al (2008) developed on matrix-type transdermal patches 
of verapamil hydrochloride (VRP) with pectin as a matrix polymer to investigate the 
influence of several terpenes on in vitro permeation of VRP through rat skin and to 
evaluate pharmacodynamic activity of transdermal formulations in rats. Matrix-type 
transdermal patches containing VRP were prepared using pectin as a matrix agent 
and propylene glycol as a plasticizer agent. Terpenes such as nerolidol, d-limonene, 
eucalpytol, menthone, and menthol were also used as a chemical enhancer to 
improve the skin penetration of VRP. The permeation studies were performed using 
Franz-type diffusion cells and full-thickness excised abdominal rat skin. Effects of 
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terpenes on the permeation parameters of VRP were evaluated. In vitro skin 
permeation studies showed that nerolidol was the most promising enhancer among 
the enhancers examined in the present study, followed by d-limonene. 
Pharmacodynamic activity of the transdermal patches containing nerolidol or d-
limonene was evaluated in rats by the measurement of systolic blood pressure for 
360 min with the use of the tail cuff method. VRP transdermal patches significantly 
decreased the systolic blood pressure after 30 min and transdermal patches 
containing nerolidol and d-limonene maintained the decrease in blood pressure 
during the observation of 360 min. 
 Jawahar N28 et al (2007) investigated on prepare and evaluate 
Verapamil hydrochloride transdermal films and to study the effect of different 
formulation variables such as polymer concentration, polymer ratio, plasticizer 
concentration, permeation enhancer concentration, loading dose and thickness on the 
permeability and physico-chemical properties. The films were prepared by mercury 
substrate method employing chloroform as a solvent, cellulose acetate butyrate 
(CAB) and polyvinyl pyrrolidone (PVP) as polymers, dibutyl phthalate (DBP) as 
plasticizer, and isopropyl myristate (IPM) as permeation enhancer. The films were 
evaluated for film thickness, weight variation, tensile strength, drug content 
uniformity, moisture uptake, non-irritancy and stability. The drug diffusion through 
the films followed a pattern close to zero order type. The drug release profile was 
decreased with increased polymer concentration and film thickness. The films were 
comfortable with skin and stability studies indicated that the films had sufficient 
suitability and shelf-life. 
 Swarnlata S29 et al (2006) Developed Transdermal delivery of Timolol 
maleate for both reservoir as well as matrix system. The physically stable patches 
regarding drug contents, tensile strength, toughness and WVT were found for PVA 
10% and HPMC: E.C (2:8) formulation. The reservoir system followed zero order 
while the matrix system followed first order release profile. Among both matrix 
systems PVA 10% patch have more permeability than HPMC: EC (2:8) patch. 
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 Amnuaikit C30 et al (2005) Developed the suitable film formulations of 
Propranolol Hydrochloride (PPL) containing enhancers for transdermal use, 
polymeric film formulations were prepared by employing ethyl cellulose (E.C) and 
polyvinyl pyrrolidone (PVP) as a film former, and dibutyl phthalate (DBP) as a 
plasticizer. Terpenes such as menthol and cineole, and propylene glycol (PG) were 
also employed as a chemical enhancer to improve the skin penetration of PPL. In 
vitro skin permeation study showed that cineole was the most promising enhancer 
among the enhancers examined and suggested that the suitable compositions of film 
preparation would be E.C: PVP: PPL = 6:3:4 with 10% (w/w) cineole and 7:2:4 with 
10% (w/w) PG and cineole, which provided high skin permeation rates at 
93.81 ± 11.56 and 54.51 ± 0.52 μg/cm2/h, respectively. 
 Mutalik S31 et al (2004) Prepared Glibenclamide transdermal patches 
using different ratios of ethyl cellulose (EC)/polyvinylpyrrolidone (PVP) and 
Eudragit RL-100 (ERL)/Eudragit RS-100 (ERS) by solvent evaporation technique. 
The patches were subjected to skin irritation test (by both visual observation and 
histopathological evaluation), oral glucose tolerance test and pharmacokinetic 
evaluation in mice. The results revealed that the patches successfully prevented the 
severe hypoglycemia in the initial hours, which is the major side effect associated 
with oral route. The patches maintained similar effect during long-term treatment 
also. The transdermal systems produced better improvement with all the tested 
biochemical parameters compared to oral administration. The better in-vivo 
performance of the transdermal patches of glibenclamide in comparison with oral 
administration could be due to day-to-day glycemic control on long-term 
application. 
 Meier M. M32 et al(2004) Studied the influence of plasticizer poly 
(caprolactone triol) (PCL-T) and pore forming agent water on  cellulose acetate 
(CA) membrane morphology, porosity and the permeation coefficient of a model 
drug (paracetamol) . The addition of water, a non-solvent, during the membrane 
casting process was found to be a simple and effective way to change membrane 
porosity and consequently the drug permeation profile. When small quantities of non 
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solvent were used to obtain low porosity membranes, the presence of a plasticizer 
agent could be used to better modulate drug permeation. Combining the addition of 
PCL-T with the use of a non solvent resulted in a series of CA membranes with 
paracetamol permeation coefficient values in the range of ca. 10
−7
 to 10
−5
 cm s
−1
. 
 Kusum Devi V33 et al (2003) developed Transdermal patches of 
verapamil hydrochloride were prepared using four different polymers (individual 
and combination): Eudragit RL100 (ERL100), Eudragit RS100 (ERS100), 
hydroxypropyl methylcellulose 15 cps (HPMC), and ethyl cellulose (EC), of varying 
degrees of hydrophilicity and hydrophobicity. The effect of the polymers on the 
technological properties, i.e., drug release, water vapor transmission rate (WVTR), 
and percentage moisture loss (ML), percentage moisture absorption (MA), folding 
endurance, and thickness, was investigated. Different formulations were prepared in 
accordance with the 2(3) factorial design, with ERL100 being the parent polymer. 
The patch containing ERL100 alone showed maximum WVTR, % MA, and % ML, 
which could be attributed to its hydrophilic nature. As expected, substitution with 
ERS100, HPMC, and EC decreased all the above values in accordance with their 
decreasing degree of hydrophilicity. In vitro release studies showed zero-order 
release of the drug from all the patches, and the mechanism of release was diffusion 
mediated. Moreover, the release of the drug was sustained and it extended over a 
period of 24 hr in all formulations. A12 emerged as the most satisfactory 
formulation insofar as its technological properties were concerned. Further, release 
and permeation of the drug from the most satisfactory formulation (A12) was 
evaluated through different biological barriers (shed snake skin, rabbit skin, and rat 
skin) to get an idea of the drug permeation through human skin. Shed snake's skin 
was found to be most permeable (82.56% drug release at 24 hr) and rat skin was 
least permeable (52.38%). Percutaneous absorption studies were carried out in 
rabbits. The pharmacokinetic parameters calculated from blood levels of the drug 
revealed a profile typical of a sustained release formulation, with the ability to 
maintain adequate plasma levels for 24 hr. [AUC: 3.09 mg/mL hr, Cmax: 203.95 
microg/mL, Tmax: 8 hr]. It can therefore be concluded that the patch containing 
ERL100 and HPMC in the ratio 8:2 has achieved the objectives of transdermal drug 
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delivery system, such as avoidance of first pass effect, extended release, and reduced 
frequency of administration.  
 Wang F. G34 et al (2002) Casted the cellulose acetate membranes with 
acetone as a solvent at 22 and 40 °C. Polyethylene glycol (PEG, MW 600) was used 
as a pore forming agent. The in-vitro release rates of scopolamine base as a model 
drug through the membranes were evaluated in phosphate buffer solution (PBS, pH 
7.4) at 32 °C. It was observed that the drug permeation through the cellulose acetate 
membranes was obviously affected by the incorporated PEG content and formed 
membrane morphology. 
 Nguyen V35 et al (2000) evaluated the effect of ethyl cellulose on the 
delivery of estradiol and norethindrone acetate. Transdermal systems were 
fabricated by utilizing drug-in-adhesive matrix technology and were evaluated for 
the delivery rate in-vitro using human cadaver skin. The conclusion is that ethyl 
cellulose   has the ability to sustain the delivery rate of estradiol and norethindrone 
acetate over seven days. 
 K. L. K Paranjothy36 et al (1997) An attempt has been made to develop 
Transdermal patches of Verapamil HCI by using Sodium Carboxymethyl Guar as 
Polymer matrix, Propylene glycol as the plasticiser and Alupoly foil as the backing 
membrane. A comparison of various polymers and plasticisers were also made. In 
vitro release studies through mouse skin have shown that Sodium Carboxymethyl 
Guar as a suitable polymer. The primary skin irritatancy tests have shown that the 
transdermal patches are non irritant.  
 Rao, P. R37 et al  (1997) Studied the influence of casting solvent on the 
permeability of free films of ethyl cellulose with a view to develop a suitable rate 
controlling membrane for  transdermal use The casting solvent showed a significant 
influence on the mechanical as well as permeability characteristics. It was concluded 
that the plasticized free films of ethyl cellulose casted from chloroform can be used 
as rate controlling membranes to develop transdermal drug delivery systems. 
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 Bhatt, D C38 et al (1995) Conducted the diffusion studies of 
promethazine hydrochloride. The studies revealed that the films prepared from ethyl 
cellulose:povidone (polyvinylpyrrolidone) (80:20) gave zero order diffusion profile 
and it was suitable as a rate controlling membrane. 
 Phuapradit W39 et al(1995) Prepared some polymeric membranes and 
evaluated for mechanical properties and permeability to a model drug, theophylline. 
Cellulose acetate and ethyl cellulose membranes were effective in preventing the 
diffusion of theophylline. The addition of Eudragit RL-100 to cellulose acetate and 
ethyl cellulose membranes increased permeability but decreased mechanical 
strength. 
 Chowdary K. P40 et al(1994) Prepared membrane moderated 
transdermal drug delivery (TDD) systems, of various types of semisolid 
formulations and evaluated for their suitability as drug reservoirs for TDD systems 
by studying diffusion of diclofenac sodium from various bases through cellulose 
acetate (CA) membranes and rat abdominal skin alone and in combination. It was 
concluded that a membrane moderated TDD system for diclofenac sodium could be 
designed employing CA films as rate controlling membranes and sodium alginate 
and carbopol gels as drug reservoirs. 
 Bialik W41 et al (1992) Investigated the potential of the amphoteric 
substance, carboxyl betaine, to enhance the transdermal delivery of drugs, the 
compound was synthesized and incorporated into several matrices of varying 
thicknesses and drug concentrations; the release rate of chloramphenicol was 
evaluated in-vitro. Results indicated that carboxyl betaine enhances the release rate 
of the tested chemicals from thin films formed by cellulose acetate. 
 Baichwal M. R42 et al (1988) Conducted in-vitro and in-vivo studies of 
transdermal polymeric films comprised of ethyl cellulose and poly vinyl pyrrolidone 
(povidone; I), and containing either one, 2, or 4 mg of salicylic acid (II) per 2.5 sq 
cm, The study concluded that results of II release, regardless of I concentration or 
laminate thickness, showed this transdermal formulation to be promising. 
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 Friedman M43 et al (1980) Studied diffusional mass transfer across a 
serial 2 or 3 unit laminate barrier of ethyl cellulose and polyethylene glycol 
membranes was studied using caffeine and salicylic acid as model drugs. The overall 
membrane diffusional resistance was found to be the sum of the intrinsic membrane 
resistances. When the resistance of one layer was much higher than that of the 
others, the permeability was then controlled by the single layer in the laminate. 
 Donbrow M44 et al (1980) studied drug release characteristics in 
laminated double layer film systems, with salicylic acid, tripelennamine, barbitone 
(barbital) or caffeine, dispersed in hydroxypropyl cellulose (I) and attached to 
ethylcellulose films containing various proportions of polyethylene glycol 4000 or 
hydroxypropyl cellulose to enhance permeability. Drug release in vitro followed 
zero order kinetics, rate constants being dependent on the thickness of the drug free 
membrane. Release rates were enhanced by addition of hydrophilic polymer to the 
drug free membrane. 
 Barry B. W45 et al (1976) Investigated the permeation across cellulose 
acetate of 3 estrogens, differing only in the number of hydroxyl groups attached to 
the nucleus, and a standard steroid, dexamethasone, using the lag time method for 
calculating diffusion parameters between 10DG and 40DG. The results implied that 
steroid diffusion occurred through aqueous membrane channels, but that it was 
impeded to various extents by both obstruction and polar interaction effects. 
 Barry B.W46 et al (1976) investigated permeation of hydrocortisone, 
dexamethasone, testosterone and progesterone across cellulose acetate membranes 
between 10DG and 40DG. The process depended mainly on membrane water 
partition coefficients of the steroids so that the least polar compound permeated the 
fastest. 
 Short P. M47 et al (1970) Investigated the effect of the surfactants upon 
the diffusion of testosterone through cellulose acetate membranes. Diffusion 
coefficients were calculated using a method that allows the measurements to be 
completed in a very short time. Possible mechanisms by which surfactants may 
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affect drug transport are discussed. In all cases examined, the surfactants reduced the 
diffusion coefficient of testosterone. 
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4. SCOPE AND OBJECTIVE OF THE WORK 
 
 Verapamil hydrochloride is a calcium ion influx inhibitor. It is widely 
used in the treatment of angina, hypertension, and supraventricular tachyarrhythmia. 
The plasma half-life of verapamil HCl is 2-7 hrs, which necessitates multiple dosing. 
It is approximately 90% absorbed from the gastrointestinal tract but is subject to 
considerable first pass metabolism and its bioavailability is around 20-30%. It 
undergoes variable and extensive first pass metabolism before entering into systemic 
circulation and varies with species. The transdermal administration of drugs, 
exhibiting oral first pass metabolism, may improve the bioavailability and reduces 
the dosing frequency when compared to the oral route. 
 Treatment for hypertension is a long term therapy where noncompliance 
is high. Hence prolonged release dosage forms are required for quality health care. 
The hypertension condition requires the continuous availability of antihypertensive 
drug in the systemic circulation. Due to its low biological half life (2-7hrs), 
Verapamil requires frequent administration. Sustained therapeutic action is 
necessary for alleviating patient‟s symptoms and is achieved by transdermal drug 
delivery systems. Transdermal drug delivery systems are designed to compliment 
pharmaceutical activity of the medicament in order to achieve the longer duration of 
action. 
 In the present investigation on membrane moderated therapeutic systems 
by employing Ethyl cellulose, Cellulose acetate polymeric films as a rate controlling 
membranes with an objective of developing transdermal formulations to obtain 
controlled release of Verapamil HCl. 
 Though the polymeric film and drug reservoirs have been studied for 
controlled release, no attempts were made to study the influence of casting solvent, 
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polymer film and drug reservoir on permeability of Verapamil HCl. The solvent 
employed in the preparation of polymer films is likely to influence the permeability 
of drug. In the present investigation the influence of four different solvents namely 
Acetone, Dichloromethane, Chloroform & Ethyl acetate was studied. 
 In the present work, Ethyl Cellulose, Cellulose acetate films were 
prepared and evaluated as rate controlling membrane for transdermal drug delivery 
systems. Solvent evaporation and Casting on mercury surface techniques were 
employed in the present work for the preparation of films. In each case films were 
prepared using solutions of the polymer in various solvents to evaluate the influence 
of the solvent used on the mechanical and permeability properties of the films.  
The Major Objectives of the Investigation are as Follow: 
1. To investigate the interactions existing among drug and polymers 
by FTIR spectral studies.  
2. To evaluate the influence of casting solvent on the permeability of 
the Polymeric films. 
3. To develop and design membrane moderated transdermal drug 
delivery systems for Verapamil HCl by using Ethyl Cellulose, 
Cellulose acetate polymers as rate controlling membrane. 
4. To characterize  the rate controlling membrane for 
a. Physical appearance.   
b. Thickness uniformity.  
c. Folding endurance. 
d. Water vapour transmission.  
e. Drug diffusion. 
f. Permeability Co efficient. 
g. Diffusion flux. 
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5. Preparation of a drug reservoir gel with different and combination 
of hydrophilic  polymers.  
6. To study the effect of permeation enhancers on permeability of 
Verapamil HCl. 
7. To conduct the stability studies for the best gel formulation. 
8. To develop the membrane moderated transdermal therapeutic 
system by optimizing the rate controlling membrane and casting 
solvent and studied the permeation of drug from the gels 
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5. MATERIALS & METHODS 
 
Table 1: Materials 
S.No Materials Manufacturer’s Name 
1.  Verapamil HCl Hetero Drugs, Hyderabad 
2.  Cellulose acetate(100-140 cps) Himedia; Mumbai 
3.  Ethyl cellulose (48-49.5%) Himedia; Mumbai 
4.  Acetone Qualigens; Mumbai 
5.  Ethyl acetate S. D. Fine-Chem Ltd.; Mumbai 
6.  Dichloromethane S. D. Fine-Chem Ltd.; Mumbai 
7.  Chloroform S. D. Fine-Chem Ltd.; Mumbai 
8.  Dibutyl phthalate Ranbaxy Laboratories; New Delhi 
9.  Propylene glycol S. D. Fine-Chem Ltd.; Mumbai 
10.  Ethanol Qualigens; Mumbai 
11.  Methanol Qualigens; Mumbai 
12.  Sodium carboxy methyl cellulose  
(200-300cps) 
S. D. Fine-Chem Ltd.; Mumbai 
13.  Carbopol 934 Arihanth traders; Mumbai 
14.  Hydroxy propyl methyl cellulose(50 cps) S. D. Fine-Chem Ltd.; Mumbai 
15.  Methyl cellulose (28-32%) S. D. Fine-Chem Ltd.; Mumbai 
16.  Glycerin S. D. Fine-Chem Ltd.; Mumbai 
17.  Mercury Qualigens; Mumbai 
18.  Poly ethylene glycol 6000 Qualigens; Mumbai 
19.  Poly vinyl pyrrolidone Qualigens; Mumbai 
20.  Dimethyl sulfoxide Qualigens; Mumbai 
21.  Poly ethylene glycol 400 Qualigens; Mumbai 
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Table 1: (Continued)  
22.  Tween 20 Qualigens; Mumbai 
23.  Sodium lauryl sulphate Qualigens; Mumbai 
24.  Hydrochloric Acid Qualigens; Mumbai 
25.  Sodium hydroxide Qualigens; Mumbai 
26.  Potassium di hydrogen ortho phosphate Qualigens; Mumbai 
27.  Potassium chloride Qualigens; Mumbai 
28.  Calcium chloride Qualigens; Mumbai 
 
Table 2: Equipments 
S.No Materials Manufacturer’s Name  
1 U. V. Spectrophotometer Elico; Hyderabad; Model: SL 159 
2 Analytical Balance (200 D) Dhona; Calcutta 
3 Ultra Sonicator PCI Limited; Mumbai 
4 Magnetic Stirrer Remi; Mumbai 
5 Hot Air Oven Lawrence & Mayo; Sec‟bad 
6 pH meter Systronics Digital –DI-707 
7 Fronz Diffusion cells Labindia, Mumbai. 
 
CALIBRATION CURVE FOR VERAPAMIL HCl 
 Accurately weighed 50mg of Verapamil HCl and was dissolved in 
ethanol in a 50 ml volumetric flask and the solution was made up to volume with 
ethanol. 
 The standard solution of Verapamil HCl was subsequently diluted with 
phosphate buffer of pH 7.4 to obtain a series of dilutions containing 2, 4, 6, 8 and 10 
µg of Verapamil HCl per 1 ml of solution. The absorbance of the above dilutions 
was measured in Shimadzu double beam UV spectrophotometer at 278 nm using the 
phosphate buffer of pH 7.4 as a blank
48
. The concentrations of Verapamil HCl and 
99 
the corresponding absorbance values are given Table 7. The absorbance values were 
plotted against concentrations of Verapamil HCl as shown in Figure 12.   
COMPATIBILITY STUDIES
49
 
 The IR spectra for the Verapamil, Cellulose acetate, Ethyl cellulose, were 
recorded on JASCO FT-Infra red spectrophotometer using KBr pellet technique 
(1:100) at the resolution rate of 4cm
-1 
and shown in the figures 13,14,15. Spectrum 
was integrated in transmittance mode at the wave number range 400 to 4000 cm
-1
. 
PREPARATION OF DRUG FREE FILMS 
Cellulose Acetate and Ethyl Cellulose Films: 
 Solvent evaporation technique
50 
was employed in the present work for the 
preparation of Cellulose acetate and Ethyl cellulose films. The composition of the 
films was showed in Table 3. 
 The polymer solutions were prepared by dissolving the polymer (2% w/v 
Cellulose acetate or 2% w/v Ethyl cellulose) in 20 ml of four different solvents 
namely, Acetone-Methanol (8:2), Chloroform-Methanol (8:2), Dichloromethane-
Methanol (8:2), and Ethyl acetate-Methanol (8:2). Dibutyl phthalate at a 
concentration of 40% w/w of the polymer was used as a plasticizer. The resulting 
solution was made up to 50 ml with casting solvents separately. 20 ml of the 
polymer solution was poured in a Petri plate (9.4 cm diameter) placed on a 
horizontal flat surface. The rate of evaporation was controlled by inverting a funnel 
over the Petri plate. After 24 hours the dried films were taken out and packed in a 
aluminium foil. 
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Table 3: Composition of Ethyl Cellulose and Cellulose Acetate Drug Free Films 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
Ethyl Cellulose (mg) 1000 1000 1000 1000 --- --- --- --- 
Cellulose Acetate (mg) --- --- --- --- 1000 1000 1000 1000 
n-dibutylphthalate(ml) 
40%w/w  
of polymer 
40%w/w  
of polymer 
40%w/w  
of polymer 
40%w/w  
of polymer 
40%w/w  
of polymer 
40%w/w  
of polymer 
40%w/w  
of polymer 
40%w/w  
of polymer 
Acetone + Methanol (ml) (8:2) up to 50 --- --- --- 50 --- --- --- 
Dichloromethane + Methanol (ml) 
(8:2) up to 
--- 50 --- --- --- 50 --- --- 
Chloroform+ Methanol (ml) (8:2)        
up to 
--- --- 50 --- --- --- 50 --- 
Ethyl Acetate + Methanol (ml) (8:2)    
up to 
--- --- --- 50 --- --- --- 50 
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DOSE DESIGN 
 The mathematical description of drug release that follow zero order 
kinetics is based on the equation
51
. 
 K
o
r=KeCdVdBw 
Where, K
0
r is zero order rate constant for drug release,  
 Ke is first order rate constant for overall drug elimination,  
 Cd is desired drug level in the body,  
 Vd is volume space in which drug is distributed and 
 Bw is normal human body weight. 
 For Verapamil Hydrochloride
52 
t½ = 5.1 hr,
 
Vd =4 l/kg and Cd = 0.05 
µg/ml and therefore the desired drug release rate can be calculated as follows 
 K
0 
r = (0.693/5.1)×0.05 ×4 ×70 =1.90 mg/h 
For 24 hrs the required dose =1.90 X 24 = 45.6 mg=50mg 
EVALUATION OF RATE CONTROLLING MEMBRANE 
 All the rate controlling membranes were evaluated for the following 
parameters. 
Thickness: 
 The thickness of the films was measured by a „Screwguage‟. The mean 
of the five observations were calculated and the readings are shown in Table 8.  
 
57 
Tensile strength & Percentage of Elongation
53
: 
 Tensile strength was calculated using “Tensile meter”. Percent elongation 
was calculated as the ratio of the difference in length after pulling to its initial length 
and the readings are shown in Table 8. 
Folding Endurance
54
: 
 The folding endurance was measured manually for the prepared films. A 
strip of film (2x2 cm) was cut evenly and repeatedly folded at the same place till it 
broke. The number of times the film could be folded at the same place without 
breaking give the exact value of folding endurance and the readings are shown in 
Table 8.                                       
Water vapour Transmission (W.V.T) Rate
55
: 
 For the study vials of equal diameter were used as transmission cells. 
These cells were washed thoroughly and dried in an oven. About 1.0 gm of Calcium 
chloride was taken in the cell and the polymeric films measuring 3.14 cm
2
 area were 
fixed over the brim with the help of an adhesive. The cells were weighed accurately 
and initial weight is recorded, and then kept in a desiccator containing saturated 
solution of KCl (about 200 ml.). The humidity inside the desiccator was measured 
by a hygrometer, and it was found to be in between 80 – 90 % RH. The cells were 
taken out and weighed after 18, 36 54 and 72 hrs. 
  From increase in weights the amount of water vapour transmitted and the 
rate at which water vapour transmitted were calculated by using the following 
formula                                  
 S
WL
  (W.V.T) Rateon TransmissiVapour Water 
 
Where, W = Water vapour transmitted in gms. 
 L = Thickness of the film in cm. 
 S = Exposed surface area in cm
2 
58 
 
Figure 10: Hygrometer 
 The readings are shown in Table 9. 
Drug Diffusion Study: 
 Drug diffusion study was conducted using Franz diffusion cell
56
.  The 
receptor compartment was filled with 15 ml of phosphate buffer having pH 7.4 as 
diffusion media. Polymeric film was mounted on the donor compartment with the 
help of an adhesive.  
 10 ml of the 0.25% W/V of drug solution was poured into the donor 
compartment. Magnetic stirrer was set at 50 rpm and whole assembly was 
maintained at 32 + 0.5°C. The amount of drug released was determined by 
withdrawing 1 ml of sample at regular time intervals for 3 hours. The volume 
withdrawn was replaced with equal volume of fresh buffer solution. Samples were 
analyzed for drug content using a U V spectrophotometer at 278 nm. The readings 
are shown in Table 10. 
FORMULATION OF DRUG RESERVOIR GELS 
 Different drug reservoir gels were formulated as per the composition 
given in Table 4. The required quantities of polymer was weighed and transferred 
separately into a mortar. It was triturated with 10 ml of water. Specified amount of 
Verapamil hydrochloride, methylparaben and propylparaben were weighed 
accurately and dissolved in glycerin. The resulting drug solution was incorporated 
59 
into the polymer dispersion slowly with continuous trituration to obtain a gel. In 
case of carbopol gel, specified amount of carbopol 934 was soaked in 20 ml of water 
over night. Specified amount of Verapamil hydrochloride, methylparaben and 
propylparaben were weighed accurately and dissolved in glycerin. The resulting 
drug solution was incorporated into the polymer dispersion with stirring at 500 rpm, 
by a magnetic stirrer for 1 hr. The pH of above mixture was adjusted to neutral with 
tri ethanolamine (0.5%). The gel was transferred in to a measuring cylinder and the 
volume was made up to 20 ml with distilled water.  
Table 4: Composition of Verapamil Hydrochloride Gels Containing Various 
Polymers 
Ingredients G1 G2 G3 G4 
Verapamil hydrochloride (mg) 1000 1000 1000 1000 
Sodium carboxy methyl cellulose (mg) 800 --- --- --- 
Carbopol 934 (mg) --- 800 --- --- 
Methyl cellulose (mg) --- --- 800 --- 
HPMC (mg)                                     --- --- --- 800 
Methylparaben(mg) 20 20 20 20 
Propylparaben(mg) 10 10 10 10 
Tri ethanolamine (0.5%) --- q.s --- --- 
Glycerin (ml) 2 2 2 2 
Distilled water (ml) up to 20 20 20 20 
 
EVALUATION OF DRUG RESERVOIR GELS 
 The drug reservoir gels formulated with HPMC, Sodium carboxy methyl 
cellulose, Methyl cellulose and Carbopol 934 were evaluated for the following 
parameters 
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Drug content: 
 The Verapamil hydrochloride gel (1gm containing 50 mg) was dissolved 
in 50 ml of phosphate buffer (pH 7.4) solutions. The absorbance was measured after 
suitable dilution at 278 nm respectively against the corresponding blank solution. 
The blank solutions were the gels free from drug. The readings are shown in  
Table 11. 
pH and viscosity
57
: 
 The pH of the dispersion was measured using pH meter (Systronics 
Digital –DI-707).The pH of the gels were measured before and after the 
incorporation of the drug. Viscosity of the gels was determined using a Brook field 
viscometer. The readings are shown in Table 11. 
Spreadability
58
: 
 Spreadability of formulation was determined with the apparatus proposed 
&fabricated by Multimer et al. It consists of wooden block provided with two glass 
slides. Lower slide was fixed on wooden block and upper slide with one end was 
tied to glass slide and other end tied to weight pan. A gel equivalent to 2.5 g was 
placed between two slides and 1000 g weight was placed over it for 5 minutes to 
press the sample to a uniform thickness. 100g of weight was added to pan. The time 
(in seconds) required by the top glass slide to travel a distance of 10cm is noted. 
This was taken as a measure of spreadability. Shorter time interval to cover the 
distance of 7.5 cm indicates better spreadability. The readings are shown in  
Table 11. 
Physical stability by freeze thaw method
59
:  
 Stability testing was done by using freeze thaw cycling method. The 
temperature was altered every 24 hours between 25
°
C and -5
°
C for five cycles and 
samples were observed for physical stability, homogeneity and synersis 
61 
(spontaneous contraction of gel exuding some of the fluid medium).  The readings 
are shown in Table 11. 
Drug diffusion study
60
: 
 Drug diffusion study was conducted using Franz diffusion cell. The 
receptor compartment was filled with 15 ml of phosphate buffer having pH 7.4 as 
diffusion media. Cellulose acetate film was mounted on the dialysis membrane with 
the help of an adhesive. 1 gm of gel (50 mg of Verapamil hydrochloride) was placed 
on the film. Dialysis membrane was kept between the receptor compartment and the 
donor compartment. Magnetic stirrer was set at 50 rpm and whole assembly was 
maintained at 32 + 0.5
°
C. The amount of drug released was determined by 
withdrawing 1 ml of sample at regular time intervals for 3 hours. The volume 
withdrawn was replaced with equal volume of fresh buffer solution. Samples were 
analyzed for drug content using a UV spectrophotometer at 278 nm. The readings 
are shown in Table 12. 
FORMULATION AND EVALUATION OF GELS WITH COMBINATION 
OF POLY VINYL PYRROLIDINE AND POLY ETHYLENE GLYCOL 6000 
 Two different hydrophilic polymers polyvinyl pyrrolidone and poly 
ethylene glycol 6000 were incorporated into sodium carboxy methylcellulose gels to 
enhance the permeability of Verapamil hydrochloride. The composition of the 
resulting gels was showed in Table 5. These gels were also evaluated for drug 
content, pH and viscosity, spreadability, physical stability by freeze thaw method.
 
The results are shown in Table 13. Diffusion data results are shown in Table 14. 
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Table 5: Composition of Verapamil Hydrochloride Gels Containing 
hydrophilic Polymers 
Ingredients G1 G5 G6 
Verapamil hydrochloride (mg) 1000 1000 1000 
Na CMC (mg) 800 --- --- 
Na CMC: Povidone (1:1) (mg) --- 800 --- 
Na CMC: PEG 6000(1:1) (mg) --- --- 800 
Methylparaben(mg) 20 20 20 
Propylparaben(mg) 10 10 10 
Glycerin (ml) 2 2 2 
Distilled water (ml) up to 20 20 20 
 
PREPARATION AND EVALUATION OF GELS CONTAINING 
PERMEATION ENHANCERS 
 Four different permeation enhancers namely 2% w/w of sodium lauryl 
sulphate, 2% w/v of poly ethylene glycol 400, dimethyl sulfoxide and tween 20 were 
incorporated into the gels.  The composition of these gels was given in Table 6. 
These gels were also evaluated for drug content, pH and viscosity, spreadability, 
physical stability by freeze thaw method.
 
 The results are shown in Table 15. 
Diffusion data results are shown in Table 16. 
Table 6: Composition of Verapamil Hydrochloride Gels Containing Various 
Permeation Enhancers 
Ingredients GP1 GP2 GP3 GP4 
Verapamil hydrochloride (mg) 1000 1000 1000 1000 
Na CMC : PEG 6000 (1:1) (mg) 800 800 800 800 
Methylparaben(mg) 20 20 20 20 
Propylparaben(mg) 10 10 10 10 
Tween 20(ml) 0.4 --- --- --- 
Sodium lauryl sulphate (mg) --- 0.4 --- --- 
Dimethyl sulfoxide (ml) --- --- 0.4 --- 
Polyehylene glycol 400 (ml) --- --- --- 0.4 
Glycerin (ml) 2 2 2 2 
Distilled water (ml) up to 20 20 20 20 
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STABILITY STUDIES
61
  
 The accelerated stability studies were carried out for the selected gel 
formulations under following conditions of temperature and relative humidity for 6 
weeks. 
1. 25°C ± 2°C at 60±5%RH 
2. 40°C ± 2°C at 75±5%RH 
 Known amounts of gels were taken out at regular time intervals of 1week 
for 6weeks and analyzed for drug content , physical appearance, pH, viscosity, 
extrudability, spreadability ,and degradation rate constant(K). the results are shown 
Table 17 and Table 18. 
DESIGN OF MEMBRANE MODERATED TRANSDERMAL 
THERAPEUTIC SYSTEM FOR OPTIMIZED FORMULATION 
 A circular silicon rubber ring with an internal diameter of 2.5 cm and a 
thickness of 3 mm was fixed on to a backing membrane (an imperforated adhesive 
strip; supplied by Johnson and Johnson Limited, Mumbai). This serves as a 
compartment for drug reservoir. 1 gm of medicated gel was taken into the 
compartment as a drug reservoir. Cellulose acetate membrane of known thickness 
was fixed on the ring with glue to form a membrane moderated therapeutic systems. 
A double sided adhesive strip was fixed on the rim of the ring above Cellulose 
acetate membrane. The design was shown in figure 11. 
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Components used in the design of membrane moderated TDD systems 
A – Backing membrane   B – Silicone ring 
C – Rate controlling CA membrane  D – Double sided adhesive tape 
 
Figure 11: Sectional view of membrane moderated transdermal drug 
delivery system 
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In vitro studies
62
: 
 Drug diffusion study was conducted using Franz diffusion cell. The 
receptor compartment was filled with 15 ml of phosphate buffer having pH 7.4 as 
diffusion media. The dialysis membrane was mounted between the donor and 
receptor compartment. The membrane moderated therapeutic systems of Verapamil 
hydrochloride was placed on the skin. Magnetic stirrer was set at 50 rpm and whole 
assembly was maintained at 32 + 0.5°C. The amount of drug released was 
determined by withdrawing 1 ml of sample at regular time intervals for 24 hours. 
The volume withdrawn was replaced with equal volume of fresh buffer solution. 
Samples were analyzed for drug content using a UV spectrophotometer at 278 nm. 
The results are shown in Table 19 and figure 23. Further the order of drug release 
and mechanism of drug release was studied the values are shown in table 20 and fig 
24, 25, 26 &27 
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Experimental 
Results  
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6. EXPERIMENTAL RESULTS 
 
Table 7: Calibration Curve for the Estimation of the Verapamil HCl 
Concentration (µg/ml) Absorbance 
0 0 
2 0.175±0.03 
4 0.352±0.04 
6 0.524±0.06 
8 0.708±0.02 
10 0.871±0.04 
 
 
Figure: 12: Calibration Curve for the Estimation of 
Verapamil HCl 
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Figure 13:  FTIR Spectra of Verapamil HCl
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Figure 14:  FTIR Spectra of Verapamil HCl with Cellulose acetate
70 
 
 
Figure 15:  FTIR Spectra of Verapamil HCl with Ethyl cellulose
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Table 8: Characterization of Prepared Films From F1to F8 
Formulation 
Thickness 
(µm) 
Folding 
endurance 
Tensile strength 
(Kg.cm
2
) 
Percentage 
elongation 
F1 45.95+0.15 198 54.28±0.06 36.31±0.12 
F2 45.30+0.17 223 48.29±0.10 40.55±0.16 
F3 44.28+0.26 286 52.70±0.07 35.06±0.13 
F4 46.70+0.26 164 66.18±0.05 44.05±0.15 
F5 49.88+0.65 129 58.42±0.06 36.62±0.14 
F6 54.25+0.37 196 48.36±0.07 38.41±0.13 
F7 56.75+0.15 234 49.92±0.08 33.64±0.15 
F8 51.40+0.28 132 57.21±0.05 37.74±0.12 
Mean ± SD Values Where n=3 
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Table 9: Water Vapour Transmission Data of Prepared Films From F1 to F8 
Time 
(hrs) 
Amount of Water Vapour Transmitted (gm) 
F1 F2 F3 F4 F5 F6 F7 F8 
0 0 0 0 0 0 0 0 0 
18 0.2080.04 0.1970.02 0.1510.01 0.3060.02 0.2900.01 0.270.02 0.2450.02 0.2980.04 
36 0.4120.05 0.3940.08 0.3060.05 0.6100.08 0.5760.05 0.510.01 0.4860.01 0.5960.04 
54 0.6180.04 0.5920.04 0.4530.06 0.9110.04 0.8680.04 0.770.05 0.7340.05 0.8900.025 
72 0.8380.08 0.7830.04 0.6060.07 1.1180.04 1.1520.05 1.030.08 0.9750.08 1.1890.05 
Mean ± SD Values Where n=3 
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Figure 16:  Water Vapour Transmission Profiles of Prepared Films 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 20 40 60 80
F5
F6
F7
F8
Time (hrs)
A
m
o
u
n
t 
o
f 
w
a
te
r
v
a
p
o
u
r 
tr
a
n
sm
it
te
d
(m
g
)
 
Figure 17: Water Vapour Transmission Profiles of Prepared Films From  
F5 to F8 
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Table 10: Diffusion data of drug solution through prepared films From F1 to F8 
Time 
(h) 
Amount of  Verapamil HCl Diffused (mg) 
F1 F2 F3 F4 F5 F6 F7 F8 
0 0 0 0 0 0 0 0 0 
0.5 1.076±0.05 0.81±0.02 0.698±0.07 1.247±0.01 1.430±0.02 1.254±0.04 1.074±0.02 1.968±0.05 
1 2.234±0.04 1.755±0.03 1.484±0.04 2.628±0.02 3.038±0.04 2.7328±0.06 2.327±0.04 4.205±0.02 
1.5 3.589±0.04 2.79±0.04 2.357±0.05 4.187±0.04 4.871±0.05 4.300±0.01 3.714±0.07 6.666±0.05 
2 5.070±0.02 3.96±0.02 3.36±0.08 5.925±0.02 6.837±0.02 6.0928±0.08 5.235±0.08 9.484±0.04 
2.5 6.685±0.01 5.22±0.01 4.758±0.06 7.840±0.03 9.072±0.03 8.064±0.04 6.891±0.04 12.482±0.08 
3 8.480±0.03 6.57±0.03 5.588±0.02 10.068±0.01 11.485±0.01 10.169±0.05 8.726±0.01 15.83±0.04 
Mean ± SD Values Where n=3 
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Figure 18: Diffusion Profiles of Prepared Films From F1 to F4 
 
Figure 19: Diffusion Profiles of Prepared films for F5 to F8
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Table 11: Characteristics of Verapamil HCl Gels Formulated with Different Polymers (G1 to G4) 
Formulation 
%Drug 
content 
Viscosity 
(cps) 
Spreadability 
(gm.cm/sec) 
pH 
Homogeneity Synersis Before drug 
incorporation 
After incorporation 
of drug. 
G1 98.56 1631 29.6 7.43 7.12 *** -- 
G2 99.82 4876 32.94 7.61 7.35 *** -- 
G3 99.65 1372 33.39 7.28 7.06 *** -- 
G4 99.46 1596 30.46 7.46 7.18 *** -- 
      *** Excellent            **    Good                *    Satisfactory              -- Nill 
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Table 12:  Diffusion Diffusion Data of Verapamil HCl Gel  through Cellulose 
Acetate Films From G1 to G4 
Time 
(h) 
Amount of  Verapamil HCl Diffused (mg) 
G1 G2 G3 G4 
0 0 0 0 0 
0.5 0.05±0.01 0.03±0.05 0.02±0.05 0.01±0.08 
1 0.56±0.04 0.39±0.07 0.23±0.06 0.17±0.04 
1.5 1.50±0.05 1.26±0.11 1.19±0.01 1.11±0.04 
2 2.52±0.06 2.41±0.08 2.36±0.02 2.19±0.05 
2.5 3.56±0.02 3.29±0.02 3.15±0.06 3.09±0.02 
3 4.58±0.03 4.15±0.06 4.09±0.04 3.98±0.01 
   Mean ± SD Values Where n=3 
 
Figure 20:  Diffusion Profiles of Verapamil HCl Gels through Cellulose acetate 
Film From G1 to G4 
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Table 13: Characteristics of Verapamil HCl transdermal Gels with combination of Hydrophilic Polymers (G5 &G6) 
Formulation 
%Drug 
content 
Viscosity 
(cps) 
Spreadability 
(gm.cm/sec) 
pH 
Homogeneity Synersis Before drug 
incorporation 
After incorporation 
of drug. 
G1 98.56 1631 29.6 7.43 7.12 *** -- 
G5 99.65 2895 31.42 7.52 7.31 *** -- 
G6 99.59 2685 30.88 7.45 7.23 *** -- 
        *** Excellent            ** Good          * Satisfactory         -- Nill 
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Table 14:   Diffusion Data of Verapamil HCl Gels through Cellulose acetate 
Film (G5&G6) 
Time(h) 
Amount of  Verapamil HCl Diffused (mg) 
G1 G5 G6 
0 0 0 0 
0.5 0.05±0.01 0.49±0.05 0.68±0.07 
1 0.56±0.04 1.39±0.02 1.62±0.08 
1.5 1.50±0.05 2.45±0.04 2.59±0.06 
2 2.52±0.06 3.52±0.02 3.65±0.05 
2.5 3.56±0.02 4.43±0.04 4.69±0.09 
3 4.58±0.03 5.37±0.05 5.58±0.04 
 
 
 
Figure 21: Diffusion Profiles of Verapamil HCl Gels through Cellulose acetate 
Film (G5&G6) 
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Table 15: Characteristics of Verapamil HCl Gels Containing Permeation Enhancers 
Formulation 
%Drug 
content 
Viscosity 
(cps) 
Spreadability 
(gm.cm/sec) 
pH 
Homogeneity Synersis Before drug 
incorporation 
After incorporation 
of drug. 
GP1 99.68 1100 29.06 7.33 7.32 *** -- 
GP2 99.52 1673 32.05 7.46 7.25 *** -- 
GP3 99.80 1010 33.78 7.60 7.14 *** -- 
GP4 99.88 993 32.46 7.41 7.23 *** -- 
       *** Excellent             **  Good        *  Satisfactory         -- Nill 
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Table 16:  Diffusion Data of Verapamil HCl Gels Containing Different 
Permeation Enhancers from Cellulose acetate Films (GP1 to GP4) 
Time 
(h) 
Amount of  Verapamil HCl Diffused (mg) 
GP1 GP2 GP3 GP4 
0 0 0 0 0 
0.5 0.89±0.04 0.80±0.02 0.72±0.05 0.68±0.03 
1 1.82±0.05 1.65±0.03 1.55±0.01 1.46±0.02 
1.5 2.83±0.03 2.66±0.06 2.51±0.02 2.36±0.06 
2 3.89±0.06 3.68±0.05 3.48±0.03 3.17±0.02 
2.5 4.56±0.08 4.01±0.08 3.98±0.02 3.86±0.01 
3 5.80±0.06 4.73±0.05 4.48±0.06 4.22±0.03 
     Mean ± SD Values Where n=3 
 
 
Figure 22: Diffusion Profiles of Verapamil HCl Gels Containing Different 
Permeation Enhancers through Cellulose acetate Films (GP1  
to GP4) 
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Stability Studies 
Table 17:  Physicochemical Properties of Verapamil HCl Gel (GP1) Stored at 
25
°
C ± 2
°
C at 75±5%RH. 
Physicochemical 
properties 
Time(weeks) 
S.No Parameter 0 1 2 3 4 5 6 
1 Drug content(%) 99.72 99.62 99.52 99.44 99.34 99.26 99.18 
2 Viscosity(cps) 1100 1098 1096 1094 1092 1089 1085 
3 pH 7.45 7.43 7.41 7.38 7.35 7.34 7.32 
4 
Spreadability 
(gm.cm/sec) 
29.41 29.38 29.34 29.30 29.27 29.24 29.20 
5 Homogenity *** *** *** *** *** *** *** 
6 
Degradation rate 
Constant(per day) 
0.00005 
 
Table 18:  Physicochemical Properties of Verapamil HCl Gel (GP1) Stored at 
40
°
C ± 2
°
C at 75±5%RH. 
Physicochemical 
Properties 
Time(weeks) 
S.No Parameter 0 1 2 3 4 5 6 
1 Drug content(%) 99.72 99.58 99.46 99.34 99.22 99.12 99.04 
2 Viscosity(cps) 1100 1097 1094 1091 1089 1087 1084 
3 pH 7.45 7.41 7.38 7.35 7.33 7.31 7.29 
4 
Spreadability 
(gm.cm/sec) 
29.41 29.38 29.36 29.33 29.31 29.28 29.24 
5 Homogenity *** *** *** *** *** *** *** 
6 
Degradation rate 
constant(per day) 
0.00007 
*** Excellent 
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Table 19:  In vitro study: Diffusion Data of Verapamil HCl Gel (GP1) 
Membrane Moderate Transdermal Therapeutic System For 24 
hours 
S.No Time (hrs) GP1 
1 0 0 
2 1.0 1.76±0.03 
3 2.0 3.63±0.04 
4 3.0 5.56±0.02 
5 4.0 7.60±0.01 
6 5.0 9.63±0.02 
7 6.0 11.88±0.01 
8 7.0 13.49±0.04 
9 8.0 15.24±0.02 
10 9.0 17.41±0.03 
11 10.0 19.32±0.02 
12 11.0 21.30±0.01 
13 12.0 23.13±0.04 
14 13.0 25.12±0.03 
15 14.0 27.17±0.02 
16 15.0 29.28±0.03 
17 16.0 31.34±0.03 
18 17.0 33.56±0.04 
19 18.0 35.84±0.02 
20 19.0 37.14±0.03 
21 20.0 39.37±0.02 
22 21.0 41.86±0.01 
23 22.0 43.06±0.02 
24 23.0 44.78±0.03 
25 24.0 45.3±0.04 
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Figure 23: In vitro Study: Diffusion Data of Verapamil HCl GP1 (GP1) 
Membrane Moderate Transdermal Therapeutic System For 24 
hours 
 
Figure 24: Zero Order Plot of Verapamil HCl Gel (GP1) 
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Figure 25: First Order Plot of Verapamil HCl Gel (GP1) 
 
Figure 26: Higuchi Plot of Verapamil HCl Gel (GP1) 
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Figure 27: Peppas Plot of Verapamil HCl Gel (GP1) 
 
Table 20: Diffusion Kinetics of Verapamil HCl Gel (GP1) 
Formulation 
Correlation coefficient (R) values 
Diffusion exponent 
value(n) Zero order First Order 
Higuchi 
model 
Peppas 
model 
GP1 0.9991 0.9186 0.936 0.959 1.1634 
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7. DISCUSSION 
 
Calibration curve: 
 The calibration curve was plotted against concentration versus 
absorbance for the drug Verapamil Hydrochloride with solvent saline phosphate 
buffer p
H
 7.4. The table and figure were represented in 7 and 12. The straight line 
equation with saline phosphate buffer was found to be Y=0.0876x+0.0008 and R
2
= 
0.9998. 
Compatibility studies:  
 The IR spectra of Verapamil HCl and its combination with cellulose 
acetate, ethyl cellulose were showed in Figure 13 to 15.  
 The Infrared absorption bands in the spectrum of the pure drug 
Verapamil HCl were as follows: 
Table 20: 
S.No 
Region in  
cm
-1
 
Type of 
vibration 
Functional 
group 
Range of 
region 
1. 
1689.69 
1594.12 
C=C stretching Aromatic ring 1500-1800 
2. 2234.79 CN stretching Alkyl nitrile 2200-2500 
3. 
1253.23 
1185.98 
C-O stretching 
Aromatic 
Aliphatic 
1100-1400 
4. 1023.21 C-N stretching Aliphatic 900-1200 
5. 
2958.62 
2836.90 
C-H stretching Methyl 2800-3000 
6. 2536.31 C-H stretching Aldehyde 2500-2800 
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Compatibility studies of drug and polymer: 
 The compatibility between the drug and polymers were confirmed by 
FTIR.  
 The FTIR spectrum of the physical mixtures (drug with polymer ethyl 
celllulose and cellulose acetate) was compared with pure drug. From FTIR the 
principle peaks of Verapamil Hydrochloride alone observed at wavelength.  
 1594.12(C=C stretching), 2234.79 (CN stretching), 1023.21 (C-N 
stretching), 2536.31(C-H stretching). In the FTIR spectrum of the physical mixture 
of drug and polymers, the major peaks of drugs were observed at wavelength 
1594.40 (C=C stretching), 2312.15 (CN stretching), 1083.99 (C-N stretching). 
From the spectrum it was clear that the peaks which were in pure drug were present 
in physical mixture this shows that there is no interaction between drug and 
polymers used. 
Studies on polymeric films: 
 Solvent evaporation technique was employed for the preparation of ethyl 
cellulose and cellulose acetate films.  
  In each case films were prepared using 2% w/v solutions of the polymer 
in various solvents to evaluate the influence of the solvent used on the mechanical 
and permeability properties of the films. Acetone-methanol (8:2), chloroform-
methanol (8:2), dichloromethane-methanol (8:2), and ethyl acetate-methanol (8:2) 
were used as solvents in the preparation of films. 
  The films prepared with polymer alone were found to be brittle. To 
prevent embitterment a plasticizer, dibutyl phthalate was tried at various 
concentrations ranging from 10-50% w/w of the polymer. Preliminary experiments 
indicated that lower concentrations of dibutyl phthalate were found to give rigid and 
brittle films where as higher concentrations gave soft films. Dibutyl phthalate at a 
concentration of 40% w/w of the polymer was found to give good flexible films. 
90 
Hence, dibutyl phthalate was included as a plasticizer in the preparation of ethyl 
cellulose and cellulose acetate films. 
  All the films prepared were evaluated for thickness uniformity, folding 
endurance, tensile strength, percentage elongation and the results were showed in 
Table 8. These films were found to be uniform in thickness and offered good 
mechanical strength and flexibility. Water vapour transmission studies indicated that 
the films were permeable to water vapour and the amount of water vapour 
transmitted at various time intervals was showed in Table 9 and in Figures 16  
and 17.  
 The Verapamil HCl diffusion data was represented in Table 10 and in 
Figures 18 and 19. The result shows that the formulation F8 shows highest amount 
of drug release with Ethyl Acetate-Methanol solvent. 
Studies on drug reservoir gels: 
 The design of membrane moderated transdermal drug delivery systems 
requires a suitable rate controlling membrane and a drug reservoir. The drug 
reservoir can be in either solid, semisolid or solution form. Out of the various 
semisolids dosage forms, the gels are becoming more popular due to ease of 
application and better percutaneous absorption, than other semisolids preparations. 
Gels can resist the physiological stress caused by skin flexion, blinking and 
mucociliary movement, adopting the shape of the applied area, and controlling drug 
release. With a view to design a suitable drug reservoir, various types of gel 
formulations were prepared and evaluated by studying drug diffusion from these 
formulations across the rate controlling membrane.   
 In the present study efforts were made to prepare transdermal gels of 
Verapamil HCl using polymers like Hydroxy Propyl Methyl Cellulose (HPMC), 
Sodium Carboxy Methyl Cellulose (NaCMC), Methyl Cellulose (MC) and 
Carbopol. Transdermal gels prepared with Carbopol and Hydroxy Propyl Methyl 
Cellulose were found to be white, translucent and homogenous. But gels prepared 
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with Sodium Carboxy Methyl Cellulose and Methyl Cellulose was found to be off 
white and homogenous.         
 Drug content values of the formulations were well with in the range 
between 98.56-99.82% (Table 11).The pH of all formulations was around the skin 
pH 7.06 to 7.61 reflecting no risk of skin irritation. 
 Viscosities of Verapamil HCl gels were presented in Table 12. All gels 
were found to exhibit plastic flow. It was observed that the gel formulations showed 
good homogeneity and spreadability and the data was presented in Table 12. 
 The results of the in vitro diffusion study from Verapamil HCl gels 
across the rate controlling membrane with dialysis membrane were reported in Table 
12 and   showed in Figure 20. The result shows that the amount of drug diffused 
through G1 formulation at the end of 3 hours was found to be 4.58±0.03mg. 
 The gel formulations can be graded in the following order with respect to 
the rates of release of selected drugs from them: 
 (HPMC) < (MC) < (Carbopol) < (NaCMC). 
 Based on diffusion data Sodium Carboxy Methyl Cellulose gels were 
selected for further studies. 
Influence of hydrophilic polymers from Sodium carboxy methyl cellulose gels: 
 To enhance the permeability of selected drug, various hydrophilic 
polymers namely poly ethylene glycol 6000 (PEG 6000), poly vinyl pyrolidine 
(PVP) were incorporated in 1:1 ratio (Na CMC: polymer) in to the sodium carboxy 
methyl cellulose gels. Incorporation of hydrophilic polymers accelerated the 
permeability of selected drugs. Poly ethylene glycol 6000 offered more permeability 
when compared with poly vinyl pyrrolidine. Incorporation of poly ethylene glycol 
6000 above 1:1 ratio yielded the gels with low viscosity, showed the leakage from 
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the rate controlling membrane. Hence the studies were restricted to 1:1 ratio. All 
gels were found to exhibit plastic flow.  
 It was observed that Verapamil HCl gel formulations showed good 
homogeneity and spreadability and the data was presented in Table 13. 
 The results of the in vitro diffusion study from different gels across the 
rate controlling membrane with dialysis membrane were reported in Table 14 and   
showed in Figure 21. The result shows that the amount of drug diffused through the 
G6 formulation at the end of 3 hours was found to be 5.58±0.04 mg . 
 From the diffusion data the gel formulations can be graded in the 
following order with respect to the rates of release of selected drugs from them: 
 (NaCMC) < (NaCMC +PVP) < (NaCMC+ PEG 6000). 
 Based on drug release G6 formulation (Na CMC+PEG 6000) was 
selected for further studies. 
Influences of permeation enhancers on permeability of selected drugs:  
 The stratum corneum has evolved primarily for barrier function. This 
creates difficulties in the formulation of TDDS which aims to delivery the drug via 
skin in therapeutic quantities. The search for solutions to this problem led 
investigators to employ several enhancement techniques. One approach is the co 
administration of skin permeation enhancers. Ideally, permeation enhancers are a 
chemical entity which reduces reversibly the barrier resistance of the stratum 
corneum without damaging the viable cells. A large number of substances have been 
evaluated as permeation enhancers and research is extending with the growing need 
for safe, effective accelerants. The permeation enhancers such as sodium lauryl 
sulphate (SLS), poly ethylene glycol 400 (PEG 400), dimethyl sulfoxide (DMSO) 
and tween 20 were incorporated into gels (Drug +Na CMC + PEG 6000) with a 
view to improve permeability of selected drug. 
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 It was observed that the Verapamil HCl gel formulations containing 
various permeation enhancers showed good homogeneity and spreadability. The 
data was presented in Table 15. 
 The results of the in vitro diffusion studies of Verapamil HCl gels 
containing various permeation enhancers across the rate controlling membrane with 
dialysis membrane were reported in Table 16 and showed in Figure 22. The result 
shows that for the GP1 formulation at the end of 3 hours the amount of drug diffused 
was found to be 5.80±0.04 mg.  
Stability studies of Formulation GP1: 
 The results of stability studies were showed in Table 17 and 18. The 
stability studies were performed for six weeks. There were no significant changes in 
the drug content, physical appearance, pH, viscosity and spreadability.  
Evaluation of membrane moderated transdermal therapeutic system: 
In vitro study of Verapamil HCl membrane moderated transdermal  
therapeutic system: 
 The results of the in vitro permeation study from Verapamil HCl 
membrane moderated transdermal therapeutic system were reported in Table 19 and 
were showed in Figure 23. The result shows that at the end of 24 hours the drug 
release was found to be 45.3mg. The diffusion data shows that the system followed 
zero order kinetics and showed in Figure 24. The correlation coefficient (R
2
) values 
revealed that the diffusion profiles followed zero order kinetics and the mechanism 
of drug release was governed by peppas model the values were shown in Table 20.  
The diffusion exponent of peppas plots (slope) has a value of 1.1634 (n>1), which 
indicates case II transport diffusion. 
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8. SUMMARY AND CONCLUSION  
 
 In the present work cellulose acetate and ethyl cellulose were prepared 
and evaluated as rate controlling membranes for transdermal drug delivery systems. 
 The results obtained in the present study thus indicated that the polymer 
and solvent used has significant influence on the water vapour transmission and drug 
diffusion of the films. Based on the diffusion rate the formulations can be  
arranged as  
 Cellulose Acetate > Ethyl Cellulose. 
 Among all the films, cellulose acetate films casted with ethyl acetate -
methanol (8:2) showed high rate of drug release when compared to other films.  
 The cellulose acetate films casted with ethyl acetate: methanol (8:2) 
employing dibutyl phthalate (40% w/w of dry polymer) as plasticizer was used as 
rate controlling membranes in further studies. 
 In the present study efforts were made to prepare transdermal gels of 
Verapamil HCl using polymers like hydroxy propyl methyl cellulose (HPMC), 
sodium carboxy methyl cellulose (Na CMC), methyl cellulose (MC) and carbopol. 
 The gel formulations can be graded in the following order with respect to 
the rates of release of selected drugs from them: 
 (HPMC) < (MC) < (Carbopol) < (NaCMC). 
 To enhance the permeability of selected drugs, various hydrophilic 
polymers namely poly ethylene glycol 6000(PEG 6000), poly vinyl pyrolidine 
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(PVP) were incorporated in 1:1 ratio (NaCMC: polymer) in to the sodium carboxy 
methyl cellulose gels. The gel formulations can be graded in the following order 
with respect to the rates of release of selected drugs from them: 
 (NaCMC) < (NaCMC +PVP) < (NaCMC+ PEG 6000). 
 The permeation enhancers such as of sodium lauryl sulphate (SLS), poly 
ethylene glycol 400 (PEG 400), dimethyl sulfoxide (DMSO) and tween 20 were 
incorporated into gels (Drug +NaCMC + PEG 6000) with a view to improve 
permeability of selected drugs. 
 The permeation enhancers used for increasing the permeation of drug 
could be arranged in the following increasing order according to their permeation 
rates: 
 Tween 20> SLS> DMSO > PEG 400. 
 The increased permeation rate in all these enhancers may be due to 
surfactant action. These results indicated that the non ionic surfactant tween 20 
improves the permeability characteristics of Verapamil HCl when compared with 
the other permeation enhancers. The gels containing drug, sodium carboxy methyl 
cellulose: poly ethylene glycol 6000(1:1) and tween 20 were selected as drug 
reservoirs. 
 The membrane moderated therapeutic systems of Verapamil HCl was 
subjected to in vitro skin permeation studies, drug polymer interactions studies. 
 The results of the 24 hours in vitro permeation studies revealed that the 
drug diffusion was extended over a long period of time at a controlled rate in 
Verapamil HCl membrane moderated transdermal therapeutic systems. 
 Drug polymer interaction studies clearly indicating that the drug is not 
undergo any chemical interaction with the polymers.  
 Further the permeation, pharmacokinetic and pharmaodynamic of the 
optimized formulations has to be studied with animal models.   
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